These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 3499533

  • 1. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
    Ujiie T.
    Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
    [Abstract] [Full Text] [Related]

  • 2. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T.
    Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
    [Abstract] [Full Text] [Related]

  • 3. Augmentation by OK-432 of generation of culture-induced killer cells.
    Ujiie T.
    Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
    Fukui H, Reynolds CW.
    J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
    [Abstract] [Full Text] [Related]

  • 5. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y, Morikage T, Hirata H, Sato M, Sakamoto K, Yano S.
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
    Kaji R, Yoshida H, Yanagawa T, Sato M.
    J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
    [Abstract] [Full Text] [Related]

  • 7. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
    Rahman SM, Kawashima K, Nakashima I, Nagase F.
    Cancer Res; 1988 Nov 15; 48(22):6450-4. PubMed ID: 3263189
    [Abstract] [Full Text] [Related]

  • 8. Mitomycin C-augmented production of I-A antigen-positive macrophages in tumor vaccine-primed mice.
    Kataoka T, Yamamoto T, Honjo K, Murayama T.
    Jpn J Cancer Res; 1986 Mar 15; 77(3):305-11. PubMed ID: 3009373
    [Abstract] [Full Text] [Related]

  • 9. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
    Nagarkatti M, Kaplan AM.
    J Immunol; 1985 Aug 15; 135(2):1510-7. PubMed ID: 3159794
    [Abstract] [Full Text] [Related]

  • 10. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
    Hayashi Y, Torisu M.
    Surgery; 1990 Jan 15; 107(1):74-84. PubMed ID: 2404351
    [Abstract] [Full Text] [Related]

  • 11. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.
    J Immunol; 1984 Mar 15; 132(3):1571-7. PubMed ID: 6198397
    [Abstract] [Full Text] [Related]

  • 12. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T, Uehara S, Ariga H, Tokunaga T, Kariyone A, Tamura T, Takatsu K.
    Immunology; 2006 Jan 15; 117(1):47-58. PubMed ID: 16423040
    [Abstract] [Full Text] [Related]

  • 13. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Cancer Res; 2006 Feb 01; 66(3):1809-17. PubMed ID: 16452242
    [Abstract] [Full Text] [Related]

  • 14. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
    Ishida N, Saito M, Nanjo M.
    Gan To Kagaku Ryoho; 1984 Dec 01; 11(12 Pt 2):2681-90. PubMed ID: 6508321
    [Abstract] [Full Text] [Related]

  • 15. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N, Hori T, Ohgaki K, Inamoto T, Kodama H, Tobe T.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [Abstract] [Full Text] [Related]

  • 16. Synergy of OK-432 and recombinant interleukin 2 in the antitumor immunity induction and the cytotoxic T-lymphocyte generation.
    Ujiie T.
    Jpn J Exp Med; 1990 Jun 01; 60(3):85-92. PubMed ID: 2214256
    [No Abstract] [Full Text] [Related]

  • 17. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.
    Clin Cancer Res; 1999 May 01; 5(5):1173-82. PubMed ID: 10353754
    [Abstract] [Full Text] [Related]

  • 18. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T.
    Jpn J Exp Med; 1988 Apr 01; 58(2):109-14. PubMed ID: 3261814
    [Abstract] [Full Text] [Related]

  • 19. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
    Umezawa H, Nishikawa K, Shibasaki C, Takahashi K, Nakamura T, Takeuchi T.
    Cancer Res; 1987 Jun 15; 47(12):3062-5. PubMed ID: 3495325
    [Abstract] [Full Text] [Related]

  • 20. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M.
    Cancer Res; 2004 Aug 01; 64(15):5461-70. PubMed ID: 15289356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.